Plain-English translation of NCT06781333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This pilot study is testing whether human mesenchymal stem cells ()—special cells with healing properties—can help reduce behavioral problems like agitation and aggression in people with moderate to severe Alzheimer's disease. You would receive one infusion of the medication as an addition to the antipsychotic medicines you're already taking. Researchers want to see whether this treatment might improve difficult behaviors that often accompany Alzheimer's.
Many people with Alzheimer's experience challenging behavioral symptoms like agitation, aggression, and anxiety that are difficult to control with current medications alone. This trial explores whether stem cell therapy might offer an additional tool to help manage these troubling symptoms.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic to receive one infusion of the stem cell medication, which is added to your current antipsychotic treatment. Your participation would last up to 12 weeks total, during which researchers will monitor how you respond to the treatment. A family member or close friend will be asked to help track any changes in your behavior and symptoms throughout the study.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States